Mature B-ALL/Burkitt's NHL Summary and Conclusions Combination of Rituximab and intensive chemo feasible Combination of Rituximab and intensive chemo feasible Response rate 80-90% in Burkitt / DLBCL, overall survival ~ 90% Response rate 80-90% in Burkitt / DLBCL, overall survival ~ 90% Improvement in mature B-ALL, less for pts > 55 y Improvement in mature B-ALL, less for pts > 55 y Irradiation of residual tumors effective salvage therapy Irradiation of residual tumors effective salvage therapy SCT: No prognostic factors  no indication for SCT in CR1  No stem cell apheresis any more SCT: No prognostic factors  no indication for SCT in CR1  No stem cell apheresis any more Major toxicity: mucositis Major toxicity: mucositis
{"Image DocumentName": "Adult ALL \u2013 therapeutic strategies, including Burkitt", "Image ImageDescription": "and Lymphoblastic Lymphomas. D.Hoelzer. J.W.Goethe University. Frankfurt. for the GMALL Study Group. German Multicenter Studies for Adult Acute Lymphoblastic Leukemia. Caesarea, April", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}